.
MergerLinks Header Logo

Announced

Completed

PerkinElmer completed the acquisition of Nexcelom Bioscience from Ampersand Capital for $260m.

Financials

Edit Data
Transaction Value£183m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Acquisition

cell counting instruments

Majority

Domestic

Friendly

Biotechnology

Private

Single Bidder

Completed

Private Equity

Synopsis

Edit

PerkinElmer, a biotechnology company, completed the acquisition of Nexcelom Bioscience, a provider of automated cell counting solutions, from Ampersand Capital, a middle-market private equity firm, for $260m. "Nexcelom was founded with the goal of assisting bench scientists by automating tedious and manual cell counting processes. Over the past eighteen years the company has worked closely with our customers to develop powerful tools to solve their complex challenges in rapidly developing cell-based assay and biomanufacturing markets. Ampersand's support and guidance over the past three years have been an important part of the Nexcelom story, and I feel fortunate to have had the opportunity to partner with them," Peter Li, Nexcelom Bioscience President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US